{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:54:54Z","timestamp":1757613294245,"version":"3.44.0"},"reference-count":57,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2022,7,5]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Diabetes mellitus is a common condition associated with numerous complications and comorbidities. The diabetes spectrum includes type 1, type 2 and other forms of diabetes, which may be associated with medical therapies and genetic factors. Type 2 diabetes is managed with lifestyle, oral therapies, non-insulin-based injectables and subsequently insulin. Type 1 diabetes requires insulin from the time of diagnosis. In recent years, there have been considerable developments in the therapies available to treat type 2 diabetes and some of these also afford cardiorenal protection. This review summarises the nature, complications and therapeutic advances in the field of diabetes and provides a concise review for neurologists. Managing diabetes optimally prevents complications and all medical specialties need a basic understanding of the principles involved in diabetes care.<\/jats:p>","DOI":"10.1136\/pn-2022-003395","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T13:20:22Z","timestamp":1659187222000},"page":"532-539","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Diabetes mellitus: what the neurologists need to know"],"prefix":"10.1136","volume":"22","author":[{"given":"Jeffrey Wayne","family":"Stephens","sequence":"first","affiliation":[{"name":"Diabetes Research Group, Swansea University Medical School, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Williams","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Morriston Hospital, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Chudleigh","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Singleton Hospital, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"2025090411434604000_22.6.532.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International diabetes Federation diabetes atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2025090411434604000_22.6.532.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht142"},{"key":"2025090411434604000_22.6.532.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151"},{"key":"2025090411434604000_22.6.532.4","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0806"},{"key":"2025090411434604000_22.6.532.5","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13973"},{"key":"2025090411434604000_22.6.532.6","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S002"},{"key":"2025090411434604000_22.6.532.7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","article-title":"Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the dA Qing diabetes prevention outcome study","volume":"7","author":"Gong","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025090411434604000_22.6.532.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441801"},{"key":"2025090411434604000_22.6.532.9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2213-8587(17)30362-5","article-title":"Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank","volume":"6","author":"Thomas","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025090411434604000_22.6.532.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605223142106"},{"key":"2025090411434604000_22.6.532.11","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.2337\/diabetes.54.suppl_2.S32","article-title":"Natural history of beta-cell function in type 1 diabetes","volume":"54 Suppl 2","author":"Sherry","year":"2005","journal-title":"Diabetes"},{"key":"2025090411434604000_22.6.532.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2005.07.006"},{"key":"2025090411434604000_22.6.532.13","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1670"},{"key":"2025090411434604000_22.6.532.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.056"},{"key":"2025090411434604000_22.6.532.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0667-0"},{"key":"2025090411434604000_22.6.532.16","first-page":"247","article-title":"The key role of islet dysfunction in type II diabetes mellitus","volume":"18","author":"Porte","year":"1995","journal-title":"Clin Invest Med"},{"key":"2025090411434604000_22.6.532.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.3.360"},{"key":"2025090411434604000_22.6.532.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1263-9"},{"key":"2025090411434604000_22.6.532.19","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-826163"},{"key":"2025090411434604000_22.6.532.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2004.00318.x"},{"key":"2025090411434604000_22.6.532.21","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.2147\/DMSO.S281992","article-title":"Prevalence, Patterns and Predictors of Chronic Complications of Diabetes Mellitus at a Large Referral Hospital in Ethiopia: A Prospective Observational Study]]&gt","volume":"13","author":"Sheleme","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"2025090411434604000_22.6.532.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/4504287","article-title":"Prevalence of chronic complications, their risk factors, and the cardiovascular risk factors among patients with type 2 diabetes attending the diabetic clinic at a tertiary care hospital in Sri Lanka","volume":"2018","author":"Arambewela","year":"2018","journal-title":"J Diabetes Res"},{"key":"2025090411434604000_22.6.532.23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diabres.2018.03.006","article-title":"Steroid-Induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review","volume":"139","author":"Bonaventura","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2025090411434604000_22.6.532.24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102154","article-title":"A practical guide for the management of steroid induced hyperglycaemia in the hospital","volume":"10","author":"Aberer","year":"2021","journal-title":"J Clin Med"},{"key":"2025090411434604000_22.6.532.25","unstructured":"National Institute for Health and Care Excellence . Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period, 2020."},{"key":"2025090411434604000_22.6.532.26","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30106-6"},{"key":"2025090411434604000_22.6.532.27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejim.2012.12.017","article-title":"Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease?","volume":"24","author":"Ewald","year":"2013","journal-title":"Eur J Intern Med"},{"key":"2025090411434604000_22.6.532.28","doi-asserted-by":"crossref","first-page":"e13303","DOI":"10.1111\/obr.13303","article-title":"Genetic syndromes with diabetes: a systematic review","volume":"22","author":"Shi","year":"2021","journal-title":"Obes Rev"},{"key":"2025090411434604000_22.6.532.29","first-page":"11","article-title":"Diagnostic and therapeutic implications of double diabetes","volume":"91","author":"Urakami","year":"2019","journal-title":"Horm Res Paediat"},{"key":"2025090411434604000_22.6.532.30","unstructured":"National Institute for Health and Care Excellence . Type 1 diabetes in adults: diagnosis and management, 2021."},{"key":"2025090411434604000_22.6.532.31","unstructured":"National Institute for Health and Care Excellence . Type 2 diabetes in adults: management, 2022."},{"key":"2025090411434604000_22.6.532.32","unstructured":"National Diabetes Insulin Pump Audit . What are the outcomes for people using an insulin pump? 2022."},{"key":"2025090411434604000_22.6.532.33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2017.7115","article-title":"Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 1 diabetes: the switch 1 randomized clinical trial","volume":"318","author":"Lane","year":"2017","journal-title":"JAMA"},{"key":"2025090411434604000_22.6.532.34","first-page":"174","article-title":"The association of British clinical Diabetologists UK-wide audit of FreeStyle Libre use in diabetes effect on glycaemic control","volume":"37","author":"Deshmukh","year":"2020","journal-title":"Diabetic Med"},{"key":"2025090411434604000_22.6.532.35","doi-asserted-by":"crossref","DOI":"10.7326\/L17-0730","article-title":"Continuous glucose monitoring in patients with type 2 diabetes receiving insulin injections","volume":"168","author":"Vigersky","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025090411434604000_22.6.532.36","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/dme.13406","article-title":"Experiences of closed-loop insulin delivery among pregnant women with type 1 diabetes","volume":"34","author":"Farrington","year":"2017","journal-title":"Diabet Med"},{"key":"2025090411434604000_22.6.532.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecl.2019.10.010","article-title":"HbA\n                  1c\n               : The Glucose Management Indicator, Time in Range, and Standardization of Continuous Glucose Monitoring Reports in Clinical Practice","volume":"49","author":"Carlson","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2025090411434604000_22.6.532.38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/jamapediatrics.2021.3965","article-title":"Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial","volume":"175","author":"Abraham","year":"2021","journal-title":"JAMA Pediatr"},{"key":"2025090411434604000_22.6.532.39","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1585"},{"key":"2025090411434604000_22.6.532.40","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009"},{"key":"2025090411434604000_22.6.532.41","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"2025090411434604000_22.6.532.42","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"2025090411434604000_22.6.532.43","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"key":"2025090411434604000_22.6.532.44","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"key":"2025090411434604000_22.6.532.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"2025090411434604000_22.6.532.46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"2025090411434604000_22.6.532.47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011295"},{"key":"2025090411434604000_22.6.532.48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001847"},{"key":"2025090411434604000_22.6.532.49","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041039","article-title":"Description of a cohort of type 1 diabetes patients: analysis of comorbidities, prevalence of complications and risk of hypoglycemia","volume":"11","author":"Mart\u00ednez-Ortega","year":"2022","journal-title":"J Clin Med"},{"key":"2025090411434604000_22.6.532.50","unstructured":"National Institute for Health and Care Excellence . Annual diabetes checks among indicators proposed for latest NICE QOF menu, 2014."},{"key":"2025090411434604000_22.6.532.51","unstructured":"National Institute for Health and Care Excellence . Cardiovascular disease: risk assessment and reduction, including lipid modification. Clinical guideline [CG181, 2016."},{"key":"2025090411434604000_22.6.532.52","unstructured":"National Institute for Health and Care Excellence . Hypertension in adults: diagnosis and management, 2019."},{"key":"2025090411434604000_22.6.532.53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62459-4"},{"key":"2025090411434604000_22.6.532.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"2025090411434604000_22.6.532.55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-020-00951-6","article-title":"Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials","volume":"12","author":"Williams","year":"2021","journal-title":"Diabetes Ther"},{"key":"2025090411434604000_22.6.532.56","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s13300-020-00917-8","article-title":"Semaglutide: charting new horizons in GLP-1 analogue outcome studies","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"2025090411434604000_22.6.532.57","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2022-003395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:43:59Z","timestamp":1757011439000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2022-003395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,30]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/pn-2022-003395"],"URL":"https:\/\/doi.org\/10.1136\/pn-2022-003395","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"type":"print","value":"1474-7758"},{"type":"electronic","value":"1474-7766"}],"subject":[],"published":{"date-parts":[[2022,7,30]]}}}